Article | July 28, 2026 OIG Advisory Opinion 26‑11 Offers Guardrails for Free Diagnostic Reports Read More
Article | July 02, 2026 FDA's Expanded Decision Tree: What Food Manufacturers Should Know About FDA's New Toxicity Screening Tool Read More
Article | June 23, 2026 OIG Advisory Opinion 26‑10 Signals Scrutiny of Royalty‑Based HCP Consulting Arrangements Read More
Article | June 05, 2026 Last Call: CMS Comments Due June 9 on Proposed Breakthrough Device NTAP Changes Read More
Article | May 12, 2026 Gardner Expands Compliance and Litigation Capabilities with Addition of Vivian Egbu Read More
Article | May 05, 2026 CMS Proposes Ending “Fast-Track” NTAP Pathways for Breakthrough Devices Read More
Article | April 09, 2026 FTC Turns Up the Heat on Healthcare: Key Implications for Medtech, Pharma, & Biotech Companies Read More
Article | April 07, 2026 OIG Advisory Opinion 25-11: Key Compliance Insights for Manufacturers Read More
Article | August 07, 2023 FDA Regulatory, Compliance, and Privacy Due Diligence — Finding Your Goldilocks Zone Read More
Article | July 25, 2023 FDA's Proposed Compliance "Revamp": What Does It Mean for the Agency, Industry, and Consumers? Read More
Article | July 17, 2023 FDA Publishes First Draft Guidance for Clinical Trials with Psychedelic Drugs Read More
Article | June 21, 2023 Beyond Paperwork: Assessing the Effectiveness of a Compliance Program Read More
Article | June 14, 2023 New WA Privacy Law ‘Turns The Beat Around’ on Drug and Device Makers Read More